Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, mitoxantrone, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, etoposide, ifosfamide; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 85
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Acute Liver Failure, Hepatic Encephalopathy
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 18 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 274
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more

Conditions: Crohn Disease
Interventions: Capsule Endoscopy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions: Abiraterone Acetate, Apalutamide, Degarelix, Indomethacin, Laboratory Biomarker Analysis, Prednisone; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hemorrhagic Shock, Traumatic Brain Injury
Interventions: hypertonic saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aortic Stenosis
Interventions: Lotus Valve System, CoreValve/Evolut R Transcatheter Aortic Valve Replacement System, LOTUS Edge Valve System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 1,425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 40 more

Conditions: Surgical Site Infection
Interventions: IrriSept System, No Intervention - Standard of Care (SoC) only; Device · Other
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Concussion, Brain
Interventions: Post-concussion education for families; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pain
Interventions: Prialt (ziconotide); Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 44
States / cities: Huntsville, Alabama • Northport, Alabama • Tucson, Arizona + 41 more

Conditions: Cholestasis
Interventions: Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: Davis, California • West Hollywood, California • Miami, Florida + 8 more

Conditions: Hematologic Malignancies
Interventions: PF-04449913; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: La Jolla, California • San Diego, California • Houston, Texas + 1 more

Conditions: Acute Heart Failure
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 105
States / cities: Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more

Conditions: Prostate Cancer
Interventions: sipuleucel-T; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Sexual Aggression, Heavy Drinking
Interventions: Cognitive Restructuring, Mindfulness, Alcohol consumption; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 30 Years · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Bevacizumab, Erlotinib, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Karen D. Wright MD; Other
Eligibility: 3 Years to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2; Biological · Radiation · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 68
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more

Conditions: Hypertension
Interventions: ENACTS; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Discussion, Goal Setting, Interview, Media Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Reward, Text Message-Based Navigation Intervention; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 20 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Melanoma
Interventions: INCAGN02385, INCAGN02390, INCMGA00012.; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 9 more

Search by objective public record fields.

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Hypertonic Modulation of Inflammation Following Injury

Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

Developing an Implementation Strategy for Post-concussion Communication With Low Health Literacy Parents in the Emergency Department

Prialt (Ziconotide) In Severe Chronic Pain

Linerixibat Long-term Safety, and Tolerability Study

A Study Of PF-04449913 In Select Hematologic Malignancies

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Emotion Regulation Interventions for Alcohol-Related Sexual Aggression

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies